Oncology On The Go

This week, CancerNetwork spoke with Debra Patt, MD, PhD, MBA, FASCO, Executive Vice President at Texas Oncology. Patt discussed the rise of telehealth during the COVID-19 pandemic, how clinicians can use these tools to help treat patients with cancer, and the role of telemedicine moving forward.
Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

As part of CancerNetwork’s Between the Lines video series, Brian Helfand, MD, PhD, Chief of the Division of Urology and the Ronald L. Chez Family and Richard Melman Family Endowed Chair at NorthShore University HealthSystem, and Steven Finkelstein, MD, FACRO, a radiation oncologist with Florida Cancer Affiliates US Oncology Network in Panama City, Florida, examined the results and clinical implications of the phase 2/3 EMPIRE-1 trial in prostate cancer. The trial compares 18F-fluciclovine PET/CT imaging versus conventional imaging to guide postprostatectomy salvage radiotherapy.

To watch more videos in CancerNetwork’s Between the Lines series, visit cancernetwork.com.

This episode features an examination of an article from the September issue of the journal ONCOLOGY, titled “Plasma Glutamine as a Prognostic Biomarker in Localized Prostate Cancer: Comparison of Conventional Variables in Risk Stratification.” CancerNetwork spoke with one of the authors of this research, Jun Gong, MD, a practicing medical oncologist with an emphasis in GU cancers at Cedars-Sinai Medical Center.
Gong detailed PSA’s role in prostate cancer, and other potential complementary biomarkers. He also discussed some of the significant findings from his research on plasma glutamine, which featured a cohort of over 100 patients with localized prostate cancer.

Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

This week, CancerNetwork spoke with Josh Ludwig, Global Director of Commercial Operations at ScaleReady, about how this joint venture between industry leaders launched in January, is uniquely positioned to make cell and gene therapy practical and viable.
Ludwig elaborated on how ScaleReady can support the entire industry, now and into the future, with a manufacturing platform that delivers a high throughput and efficient use of space. He also discussed G-Rex closed-system bioreactors, important processes for successful commercialization of cell and gene therapy, and what’s next for ScaleReady.
Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

CancerNetwork spoke with Quita Highsmith, Vice President and Chief Diversity Officer for Genentech, and Monica Baskin, PhD, a professor of preventive medicine and associate director for Community Outreach and Engagement for the O’Neal Comprehensive Cancer Center in Birmingham, Alabama. The conversation focused on the Advancing Inclusive Research Site Alliance, which is a coalition of clinical research sites partnering with Genentech to advance representation of diverse patient populations in oncology clinical trials.
Results from clinical trials without diverse patient cohorts are rarely generalizable to the entire population, and this initiative works to educate and inform the clinicians and researchers to ultimately make clinical trials more accessible and eliminate these disparities.

Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

For the final installment of a 3-part relapsed/refractory DLBCL series, CancerNetwork heard from Gilles Salles, MD, PhD, Chief of the Lymphoma Service at Memorial Sloan Kettering Cancer Center in New York, and Kami Maddocks, MD, an associate professor of clinical internal medicine in the Division of Hematology at The Ohio State University Wexner Medical Center.
These lymphoma experts spoke about their thoughts on data from the L-MIND trial, when to implement CAR-T cell therapies for patients, the role of Selinexor in treating patients, and a host of other important ideas.
Don’t forget to subscribe to the Oncology Peer Review On-The-Go podcast on Apple Podcasts, Spotify or anywhere podcasts are available. Be sure to check out the 2 other installments of this 3-part DLBCL series on rituximab rechallenging and different treatment regimens.

As part of its OncView™ video series, CancerNetwork® spoke with Javier Munoz, MD, MS, FACP, from the Mayo Clinic in Phoenix, Arizona, about updates in therapies of relapsed/refractory follicular lymphoma.
In the video series, Javier Munoz, MD, MS, FACP, discussed the following:
·      Current Treatment Options for Relapsed/Refractory Follicular Lymphoma

·      Factors in Choosing R/R FL Treatments

·      Treatment Options for Third-Line R/R FL

·      Use of Tazemetostat for R/R FL

·      Changes in Sequencing of R/R FL Therapies

To watch more videos in CancerNetwork®’s OncView™ series, visit cancernetwork.com/oncview.

As part of its OncView™ video series, CancerNetwork® spoke with Lee Schwartzberg, MD, FACP, of the West Cancer Center and Research Institute in Germantown, Tennessee, about updates to the National Comprehensive Cancer Network (NCCN) guidelines regarding hormone receptor (HR)–positive breast cancer.
In the video series, Lee Schwartzberg, MD, FACP, discussed the following:
·      Extended Adjuvant Therapy for HR+ Breast Cancer

·      Molecular Biomarkers for HR+ Breast Cancer

·      Role of Genomic Testing in HR Positive Breast Cancer

·      Appropriateness for Genomic Testing in HR+ Breast Cancer

·      Integration of Genomic Testing into NCCN Guidelines

·      Current Recommendations for Genomic Testing in HR+ Breast Cancer

·      Treatment Limitations in HR+ Breast Cancer

To watch more videos in CancerNetwork®’s OncView™ series, visit cancernetwork.com/oncview.
Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

This week's podcast focuses on a review article published in the June issue of the journal ONCOLOGY titled, “Routine Breast Cancer Screening in Average-Risk Women Younger Than 50 Years: Current Paradigms Based on National Guidelines.” CancerNetwork spoke with Anath Ravi, PhD, co-founder and chief science and clinical officer of MOLLI Surgical, and Randy Miles, MD, MPH, an assistant professor in the Department of Radiology and clinical service chief in the Division of Breast Imaging at Massachusetts General Hospital, about their work with breast cancer screenings for women under the age of 50.
The conversation focused on the current breast cancer screening guidelines, the risks and benefits of screening for women between the ages of 40 and 49, the different imaging techniques and what roles they play, as well as the future direction of breast cancer screening.

Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify or anywhere podcasts are available. 

This week, CancerNetwork review an article published in the July issue of the journal ONCOLOGY titled, “Level of Scientific Evidence Underlying the National Comprehensive Cancer Network Clinical Practice Guidelines for Hematologic Malignancies.” CancerNetwork spoke with Thejaswi Poonacha, MD, MBA, a staff physician and hospitalist in the department of internal medicine at the University of Minnesota Medical Center, regarding the research from him and his colleagues.
The conversation focused on the scientific evidence behind the NCCN guidelines for hematologic malignancies, how each category corresponds with different levels of evidence, and the main findings from this study. Poonacha shared exactly what this means, and why this research was so significant for this group of authors.

Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify or anywhere podcasts are available.